Dublin, Feb. 08, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering.
This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies.
FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described.
Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects.
There are connections between cytogenetics and biomarkers of genetic disorders as well as cancer. Biomarkers are very important for molecular diagnostics. Not only are molecular diagnostic technologies used for discovery of biomarkers, biomarkers are the basis of several diagnostics. As a means to understand pathomechanism of disease and as links between diagnostics and therapeutics, biomarkers are playing a role in development of personalized medicine. Application of cytogenetics extend beyond genetic disorder and cancer to diagnosis of several other diseases. Other important applications are drug discovery, and development of personalized medicine.
The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified.The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography.
Key Topics Covered:
1. Introduction
2. Technologies used for cytogenetics
3. Fluorescent In Situ Hybridization
4. Genomic Technologies relevant to Cytogenetics
5. Molecular Imaging & Single Molecular Detection
6. Role of Nanobiotechnology in Cytogenetics
7. Biomarkers and Cytogenetics
8. Applications of Cytogenetics
9. Cancer Cytogenetics
10. Cytogenetics Markets
11. Companies
For more information about this report visit http://www.researchandmarkets.com/research/hj7k24/cytogenetics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Italy Fines Apple €98.6 Million Over App Store Dominance 



